2, Kangmei Pharmaceutical (* ST Kangmei, 600518.SH) for three consecutive years of premeditated, systematic implementation of financial counterfeiting, involving an amount of about 30 billion yuan, now finally sanctioned. November 12 afternoon, the "Kangmei case" first-instance verdict came out, the court declared that Kangmei Pharmaceutical and other relevant defendants to bear the total amount of 2.459 billion yuan. The total amount of investor losses amounted to 2.459 billion yuan. 2017 April 20 for the implementation of the false statement of Kangmei Pharmaceuticals, to network media disclosure of the false statement of Kangmei Pharmaceuticals on October 16, 2018 for the day of revelation to Kangmei Pharmaceuticals circulating stock cumulative turnover rate of one hundred percent of December 4, 2018 as the base date. Stockholders who bought by public bidding between the misrepresentation implementation date and the revelation date and still hold shares of Comet Pharmaceutical after the market closes on October 15, 2018 are eligible to register their rights.
I. Kangmei Pharmaceutical Co., Ltd.
1. Kangmei Pharmaceutical Co., Ltd. is referred to as "Kangmei Pharmaceutical" (SSE: 600518), which was founded by Mr. Ma Xingtian, a private entrepreneur, in 1997, and was located in Puning City, Guangdong Province. "In 2000, the company was reorganized as a joint-stock company. It is one of the large-scale pharmaceutical private enterprises integrating the supply and marketing of pharmaceuticals, Chinese medicine tablets, Chinese herbal medicines and medical devices. The company has passed the stock split reform.
2, December 28, 2018 evening Kangmei Pharmaceuticals announcement, the company received the China Securities Regulatory Commission "Notice of Investigation".January 2, 2019, Kangmei Pharmaceuticals fell to open. As of 10:00 on the 2nd, reported 8.29 yuan, down stop block single more than 400,000 hands, turnover of more than 60 million yuan. 2019 April 30, Kangmei Pharmaceutical released up to nearly 30 billion "accounting errors". May 1, issued a letter to shareholders apologized. 2019 May 17, the Securities and Futures Commission notified Kangmei Pharmaceuticals Financial report falsification, suspected of misrepresentation and other violations of the law. May 21, 2019, Kangmei Pharmaceutical Co, Ltd, the initiative to wear a hat into the "ST Kangmei".
3, August 16, 2019 The SFC made penalties for Kangmei Pharmaceuticals and others and the person in charge of the ban on the market to inform, the actual hammer falsification behavior. The SFC intends to decide on ST Kangmei ordered to correct, give a warning and impose a fine of 600,000 yuan; Ma Xingtian and Xu Dongjin were given a warning and fined 900,000 yuan respectively; Qiu Xi-wei, Zhuang Yi-Qing and other 19 people were given a warning and fined from 100,000 to 300,000 yuan.
4, May 14, 2020, the SFC issued a decision on the penalties and debarment of Kangmei Pharmaceuticals, decided to order correction of Kangmei Pharmaceuticals, give a warning and impose a fine of 600,000 yuan, impose a fine of 900,000 yuan to 100,000 yuan ranging from 21 responsible persons, and take measures of 10 years to lifelong banning measures on the securities market for the six main responsible persons. May 10, 2021 On April 22, the Company was filed for bankruptcy and reorganization by Guangdong Jiedong Rural Commercial Bank Co. involving the case number of Yue 52 Broken Shen No. 1. The company was enforced by the court 3 times.